NO175023C - Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering - Google Patents

Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering

Info

Publication number
NO175023C
NO175023C NO882853A NO882853A NO175023C NO 175023 C NO175023 C NO 175023C NO 882853 A NO882853 A NO 882853A NO 882853 A NO882853 A NO 882853A NO 175023 C NO175023 C NO 175023C
Authority
NO
Norway
Prior art keywords
vitro diagnosis
immune complexes
procedure
inflammatory disease
circulating immune
Prior art date
Application number
NO882853A
Other languages
English (en)
Norwegian (no)
Other versions
NO882853D0 (no
NO175023B (no
NO882853L (no
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of NO882853D0 publication Critical patent/NO882853D0/no
Publication of NO882853L publication Critical patent/NO882853L/no
Priority to NO933214A priority Critical patent/NO933214D0/no
Publication of NO175023B publication Critical patent/NO175023B/no
Publication of NO175023C publication Critical patent/NO175023C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO882853A 1987-07-17 1988-06-28 Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering NO175023C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO933214A NO933214D0 (no) 1987-07-17 1993-09-09 Fremgangsm}te for diagnostisering av en pasients immunologiske kapasitet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7461687A 1987-07-17 1987-07-17
US12457787A 1987-11-24 1987-11-24

Publications (4)

Publication Number Publication Date
NO882853D0 NO882853D0 (no) 1988-06-28
NO882853L NO882853L (no) 1989-01-18
NO175023B NO175023B (no) 1994-05-09
NO175023C true NO175023C (no) 1994-08-17

Family

ID=26755855

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882853A NO175023C (no) 1987-07-17 1988-06-28 Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering

Country Status (18)

Country Link
EP (1) EP0300680B1 (de)
JP (1) JP2601520B2 (de)
KR (1) KR0131880B1 (de)
CN (1) CN1035050A (de)
AT (1) ATE142500T1 (de)
AU (2) AU1820588A (de)
CA (1) CA1326999C (de)
DE (1) DE3855527T2 (de)
DK (1) DK399288A (de)
ES (1) ES2093607T3 (de)
FI (1) FI883352A (de)
HU (1) HUT47432A (de)
IE (1) IE76914B1 (de)
IL (1) IL86862A (de)
NO (1) NO175023C (de)
NZ (1) NZ225310A (de)
OA (1) OA08890A (de)
PT (1) PT87996B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
JPH04507083A (ja) * 1989-05-19 1992-12-10 ヘム・リサーチ・インコーポレーテッド 規定された構造の短い治療用ｄｓＲＮＡ
EP0495919B1 (de) * 1989-10-11 1997-01-15 Hem Pharmaceuticals Corp. Schutz gegen schock infolge einer schädigung durch doppelsträngige rna's
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
JPH07501787A (ja) * 1991-07-16 1995-02-23 ヘム・ファーマスーティカル・コーポレーション サイトカイン機能不全の緩和法および診断法
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
SG115493A1 (en) 1998-03-20 2005-10-28 Benitec Australia Ltd Control of gene expression
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (de) 2001-01-31 2004-01-28 Nucleonics, Inc Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen
AU2005321940B2 (en) * 2004-12-29 2012-04-19 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP4183386A1 (de) * 2015-11-17 2023-05-24 Highlight Therapeutics, S.L. Neuartige pharmazeutische zusammensetzung umfassend partikel umfassend einen komplex eines doppelsträngigen polyribonucleotids und eines polyalkylenimins
CN105434341B (zh) * 2015-12-22 2018-07-10 肇庆大华农生物药品有限公司 一种兽用聚腺尿苷酸注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4140761A (en) * 1977-04-11 1979-02-20 The United States Of America As Represented By The Department Of Health, Education & Welfare Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
CN1035050A (zh) 1989-08-30
EP0300680A2 (de) 1989-01-25
NZ225310A (en) 1991-05-28
KR890001580A (ko) 1989-03-27
JP2601520B2 (ja) 1997-04-16
PT87996B (pt) 1995-03-31
EP0300680B1 (de) 1996-09-11
IL86862A (en) 1993-05-13
JPS6490126A (en) 1989-04-06
OA08890A (en) 1989-10-31
PT87996A (pt) 1989-06-30
DE3855527D1 (de) 1996-10-17
DE3855527T2 (de) 1997-04-03
ES2093607T3 (es) 1997-01-01
DK399288A (da) 1989-01-18
IL86862A0 (en) 1988-11-30
EP0300680A3 (de) 1991-06-19
AU1761195A (en) 1995-06-29
FI883352A0 (fi) 1988-07-14
IE76914B1 (en) 1997-11-05
KR0131880B1 (ko) 1998-04-17
NO882853D0 (no) 1988-06-28
ATE142500T1 (de) 1996-09-15
DK399288D0 (da) 1988-07-15
CA1326999C (en) 1994-02-15
FI883352A (fi) 1989-01-18
NO175023B (no) 1994-05-09
NO882853L (no) 1989-01-18
HUT47432A (en) 1989-03-28
AU1820588A (en) 1989-01-19
IE881894L (en) 1989-01-17

Similar Documents

Publication Publication Date Title
NO175023C (no) Fremgangmåte for in vitro diagnostisering av en innflammasjonssykdom indusert av immunkomplekser som er i omlöp, og fremgangsmåte for fremstilling av dsRNA til den in vitro diagnostisering
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
DE3888273D1 (de) Medizinischer Apparat zur Behandlung mit Ultraschall.
DE3764253D1 (de) Medizinischer saugkoerper mit roentgenkontrastmittel und verfahren zu seiner herstellung.
DE69111664D1 (de) Blutpumpe und Apparat für die extracorporale Blutzirkulation.
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
ATE79264T1 (de) Verwendung von bismuth zur herstellung von medikamenten zur behandlung von magendarmst¯rungen, die von campylobacter polyridis verursacht sind.
PT86346A (en) Method of treatment by means of the 3:-deoxitimidinene-2:(3:deoxi-2:3:-didesidrotimidine) administration to animals of hot blood infected with retrovirus
ATE122402T1 (de) Diagnose von mangelzuständen doppelsträngiger rns.
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
IT8322855A0 (it) Composizione farmaceutica per la cura delle arteriopatie periferiche.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
FI875245A0 (fi) Foerfarande foer oekande av utsoendringen av adenosin.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
ATE176154T1 (de) Verwendung von adenosin zur herstellung eines arzneimittels für kontinuierliche intravenöse infusion an menschlichen patienten
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
Hunter Biological reductionism, reductionist behaviorism, and the social economy of clinical practice.
Valdimarsdottir The effects of relaxation training and experimental stressors on the immune system.
DE3877102D1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
Rochon National Conference for Women and HIV: an update
FI875232A0 (fi) Anordning foer foerflyttning av maenniska, saerskilt en roerelsebegraensad patient.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees